Compare Crispr Therapeutics AG (CRSP) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JPMorgan Equity Premium Income ETF — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while JPMorgan Equity Premium Income ETF trades at $56.69. The key difference: JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | JEPI | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $59.88 |
52-Week Low | $44.34 | $55.29 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JEPI trades at $56.76 with no price change, showing stability amid mixed technical signals. The ETF maintains a bullish technical outlook with strong moving average support, though oscillators suggest neutral momentum. Recent dividend payments of $0.39 and $0.45 demonstrate its income-focused strategy, while financial media highlights its 8%+ yield and covered call approach as key attractions for income investors.
JEPI's covered call strategy provides consistent income but limits upside potential during bull markets. The ETF faces competition from alternatives like SPYI and tax efficiency concerns, though its active management offers drawdown protection. Current technical strength supports near-term stability, but investors should weigh income benefits against capped returns in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
